In a phase II trial with 40 metastatic melanoma patients, most of which had metastasis to the lungs, liver or lymph nodes, were treated with either 30 μg/kg or 50 μg/kg of IL-21 (269). The gene discussed is IL21; the disease is metastatic melanoma.